What is Valinor?
Valinor operates at the vanguard of the biotech sector, utilizing advanced machine learning algorithms to analyze complex clinical datasets. The company's core value proposition lies in its suite of predictive models, which empower drug developers to anticipate patient responses with unprecedented accuracy. By shifting the paradigm from traditional trial-and-error methodologies to data-driven insights, Valinor effectively reduces the financial and operational risks associated with drug development. This strategic approach not only accelerates the time-to-market for new therapies but also enhances the probability of success across diverse drug modalities and therapeutic areas, positioning the firm as an essential partner for modern pharmaceutical enterprises.
How much funding has Valinor raised?
Valinor has raised a total of $13M across 1 funding round:
Seed
$13M
Seed (2025): $13M with participation from Pelion Venture Partners, Charles River Ventures, Harpoon Ventures, and Amino Collective
Key Investors in Valinor
Pelion Venture Partners
Pelion Venture Partners manages a diverse portfolio of funds, providing strategic investment solutions tailored to both institutional and individual clients seeking long-term financial growth.
Charles River Ventures
CRV is a veteran venture capital firm with a history of supporting early-stage technology startups from inception through to IPO, known for its deep commitment to the entrepreneurial journey.
Harpoon Ventures
Harpoon Ventures focuses on backing mission-critical technologies in AI and deep tech, providing founders with both capital and strategic access to defense and infrastructure sectors.
What's next for Valinor?
With this major enterprise-level funding, Valinor is poised to scale its operations and expand its proprietary dataset infrastructure. The strategic roadmap includes deepening its predictive capabilities and broadening its reach across global therapeutic markets. As the company transitions into its next phase of growth, the focus will remain on fostering partnerships with major drug developers to integrate its models into existing R&D workflows. By maintaining a rigorous commitment to data integrity and scientific excellence, Valinor aims to solidify its market position as a foundational technology provider in the evolving landscape of digital health and precision medicine. The firm's ability to attract top-tier venture capital suggests a robust trajectory toward long-term industry leadership.
See full Valinor company page
